Treatment Considerations for Transplant-Ineligible Multiple Myeloma.
While significant advances have been made in the treatment of multiple myeloma, the management of the transplant-ineligible (TI) patient population remains challenging. The individuals enrolled in clinical trials for newly diagnosed TI patients, or those with no planned transplant, may not always be...
| Publicado en: | Oncology (08909091) Vol. 35; no. 4; pp. 170 - 178 |
|---|---|
| Autores principales: | , |
| Formato: | review tables/charts Journal Article |
| Publicado: |
MJH Life Sciences
Apr2021
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=149932434&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 149932434 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 08909091 YYT jtl: Oncology (08909091) issn: 08909091 maglogo: N pubinfo: dt: Apr2021 vid: 35 iid: 4 pid: 54670 pub: MJH Life Sciences place: Cranbury, New Jersey artinfo: ui: 149932434 149932434 149932434 10.46883/onc.2021.3504.0170 149932434 ppf: 170 ppct: 8 formats: fmt: @attributes: type: P tig: atl: Treatment Considerations for Transplant-Ineligible Multiple Myeloma. aug: au: Elnair, Radowan A. Holstein, Sarah A. affil: Hematology/oncology fellow at University of Nebraska Medical Center in Omaha, Nebraska sug: subj: Multiple Myeloma Therapy Frailty Syndrome Decision Making, Clinical Antineoplastic Agents, Combined Therapeutic Use Cancer Patients Age Factors Comorbidity ab: While significant advances have been made in the treatment of multiple myeloma, the management of the transplant-ineligible (TI) patient population remains challenging. The individuals enrolled in clinical trials for newly diagnosed TI patients, or those with no planned transplant, may not always be reflective of real-world patients, with respect to age, comorbidities, or frailty status. Likewise, results obtained from randomized relapsed/refractory studies also may not be applicable to this generally older and frailer patient population. In this review, we discuss assessment of frailty and focus on treatment options in both the newly diagnosed and relapsed/refractory settings for TI patients. We describe the patient-specific considerations that factor into treatment decisions as well as provide some guidance about management. pubtype: Academic Journal doctype: review tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|